been a holder since late 2014, have averaged down significantly in the last 12 months and participated in the last SPP to take advantage of the free options. agree SAVR is a far less riskier proposition and the company is well positioned to see this project through given the new singular focus of one business unit.
I admit it was tough waiting out the suspension period last year, but Wayne was able to pull off two deals that if not done would have seen this trial not eventuate.
cheers
nathan
Ann: SAVR Clinical Trial, page-7
-
- There are more pages in this discussion • 66 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$9.91 |
Change
-0.090(0.90%) |
Mkt cap ! $209.4M | |||
| Open | High | Low | Value | Volume |
| $10.00 | $10.00 | $9.65 | $70.76K | 7.202K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 300 | $9.80 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $9.91 | 475 | 2 |
View Market Depth
| Last trade - 16.10pm 12/11/2024 (20 minute delay) ? |
| AVR (ASX) Chart |